CompletedNot Applicable

Exploring Racial Disparities in Sleep Health and Neurocognitive Function

United States30 participantsStarted 2021-01-01

Plain-language summary

Despite longer life expectancies due to combination antiretroviral therapy (cART), the prevalence of HIV-associated neurocognitive disorders (HAND) persists thus affecting 52% of the HIV population. Poor sleep quality is commonly reported in older adults and has been related to neurocognitive impairments. This is concerning given studies have shown that up to 75% of adults with HIV experience poor sleep, and by 2020, 70% of adults with HIV will be age 50 and older. It is important to examine sleep quality as it relates to neurocognitive function and HAND in older adults with HIV given its negative impact on cART adherence. Compared to Whites with HIV, African Americans (AA) are disproportionately affected by HIV and are more likely to experience poor sleep quality. This primary goal of this 1-year cross-sectional study is to examine racial differences in sleep quality and neurocognitive function among 60 African Americans and Whites with HIV (age 50+).

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HIV+ * Identify as AA or White * 50 years old or older * Speak English Exclusion Criteria: * Alzheimer's disease or dementia * Severe neurocognitive impairment (\>7 errors on the Short Portable Mental Status Questionnaire) * Deaf or blind * Currently undergoing radiation/chemotherapy * Brain trauma with loss of consciousness greater than 30 minutes * A learning disability * Significant neuromedical comorbidities (e.g., schizophrenia) * Currently taking Efavirenz * Moderate to severe sleep apnea * Restless leg syndrome * Narcolepsy * Left handedness

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Subjective Sleep Health

Timeframe: Day 1

Sleep Onset and Wake Time

Timeframe: 7 days

Insomnia Severity

Timeframe: Day 1

Speed of Processing

Timeframe: Day 1

Executive Function

Timeframe: Day 1

Attention

Timeframe: Day 1

Spatial Visualization

Timeframe: Day 1

Verbal Learning and Memory

Timeframe: Day 1

Trial details

NCT IDNCT04015830

SponsorUniversity of Alabama, Tuscaloosa

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-01

View on ClinicalTrials.gov More HIV Dementia trials

Plain-language summary

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.